The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Rheumatoid Arthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.
Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
- Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, Taisho Pharmaceutical, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Aclaris Therapeutics, Modern Biosciences, Pfizer, Abivax, AbbVie, Bristol Myers Squibb, Kiniksa Pharmaceuticals, Oryn Therapeutics, 4D pharma plc., Landos Biopharma, Inc, Biozeus, and others, are developing therapies for the Rheumatoid Arthritis treatment
- Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, TS152, SHR0302, RC18, Otilimab, ATI-450, MBS2320, PF-06651600, Obefazimod, ABBV-154, Branebrutinib, KPL-404, ORTD-1, MRx0006, LABP-69, BZ068, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
- In July 2022, Enosi Therapeutics has established a collaboration with Hong Kong-based Danuo Science Group to further the development of two drugs that are already in Enosi’s pipeline for Greater China. The agreement included the licencing of Enosi’s Growth Factor Trap (EN-2000 Programme) and TNFR1 Blocker (EN-1000 Programme). Both programmes have the potential to be employed as hybrid medications to treat both autoimmune and cancer-related conditions. While EN-1000 is a particular TNFR1 blocker, which Enosi believes may be helpful in treating autoimmune disease, EN-2000 blocks inflammatory growth factors that promote cancer and rheumatoid arthritis.
- In February 2022, A commercialization and licence agreement was signed by Biogen Inc. and Xbrane Biopharma AB to create, produce, and market XcimzaneTM, a preclinical monoclonal antibody that is a potential biosimilar to CIMZIA® (certolizumab pegol).
- In June 2022, Positive Phase III data were provided for the biosimilar candidate BIIB800 (BAT1806) by Biogen Inc. and Bio-Thera Solutions, Ltd. 621 patients with moderate to severe rheumatoid arthritis were randomised in the double-blind, 52-week Phase III study to receive either BIIB800 or the reference tocilizumab, which was given intravenously every four weeks at a dose of 8 mg/kg for the first 24 weeks. The prospective biosimilar candidate BIIB800 exhibits an equivalent efficacy and a similar safety and immunogenicity profile to the reference tocilizumab product, according to data from the Phase III comparative clinical trial.
- In June 2022, Revolo Biotherapeutics reported that the Medicines and Healthcare products Regulatory Agency (MHRA) had given its immune-resetting drug candidate, ‘1805, an Innovative Medicines Designation, or Innovation Passport, for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). Revolo Biotherapeutics received permission to begin two Phase II trials of its autoimmune disease medication candidate “1805” in February 2022 from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Patients with moderate-to-severe active rheumatoid arthritis (RA) will be included in one experiment, and participants in another Phase II trial with non-infectious, active, intermediate, or posterior uveitis or panuveitis will be included.
Rheumatoid Arthritis Overview
Inflammatory arthritis and extraarticular involvement are two characteristics of rheumatoid arthritis (RA), an autoimmune illness of the joints. Multiple joints in both hands are frequently affected, and morning stiffness that may continue for many hours is usual.
Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
- SBT-77-7101: Sonoma Biotherapeutics
- ON104: OncoOne
- ORTD 1: Oryn Therapeutics
- TJ003234: I-Mab Biopharma Co. Ltd.
- TCK-276: Teijin Pharma
- IRL-201805: Revolo Biotherapeutics
- LY3462817: Eli Lilly and Company
- Dekavil: Philogen
- AP1189: SynAct Pharma
- RC18: RemeGen
- SM03: SinoMab Bioscience
- TS152: Taisho Pharmaceutical
- SHR0302: Jiangsu Hengrui Medicine
- Otilimab: GlaxoSmithKline
- ATI-450: Aclaris Therapeutics
- MBS2320: Modern Biosciences
- PF-06651600: Pfizer
- Obefazimod: Abivax
- ABBV-154: AbbVie
- Branebrutinib: Bristol Myers Squibb
- KPL-404: Kiniksa Pharmaceuticals
- ORTD-1: Oryn Therapeutics
- MRx0006: 4D pharma plc.
- LABP-69: Landos Biopharma, Inc
- BZ068: Biozeus
- ABBV-3373: Abbvie
- Dazodalibep: Horizon Therapeutics
Rheumatoid Arthritis Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Rheumatoid Arthritis Molecule Type
Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
- Small molecule
Rheumatoid Arthritis Pipeline Therapeutics Assessment
- Rheumatoid Arthritis Assessment by Product Type
- Rheumatoid Arthritis By Stage and Product Type
- Rheumatoid Arthritis Assessment by Route of Administration
- Rheumatoid Arthritis By Stage and Route of Administration
- Rheumatoid Arthritis Assessment by Molecule Type
- Rheumatoid Arthritis by Stage and Molecule Type
DelveInsight’s Rheumatoid Arthritis Report covers around 100+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies
Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are – Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, and others.
Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
- Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies
Rheumatoid Arthritis Pipeline Market Drivers
- Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of RA, rich emerging pipeline, acceptance of biosimilars for treatment of RA are some of the important factors that are fueling the Rheumatoid Arthritis Market.
Rheumatoid Arthritis Pipeline Market Barriers
- However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA, delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.
Scope of Rheumatoid Arthritis Pipeline Drug Insight
- Coverage: Global
- Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, Taisho Pharmaceutical, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Aclaris Therapeutics, Modern Biosciences, Pfizer, Abivax, AbbVie, Bristol Myers Squibb, Kiniksa Pharmaceuticals, Oryn Therapeutics, 4D pharma plc., Landos Biopharma, Inc, Biozeus, and others
- Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, TS152, SHR0302, RC18, Otilimab, ATI-450, MBS2320, PF-06651600, Obefazimod, ABBV-154, Branebrutinib, KPL-404, ORTD-1, MRx0006, LABP-69, BZ068, and others
- Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
- Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers
Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials
Table of Contents
1. Rheumatoid Arthritis Report Introduction
2. Rheumatoid Arthritis Executive Summary
3. Rheumatoid Arthritis Overview
4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Late Stage Products (Phase II/III)
7. Rheumatoid Arthritis Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Early Stage Products (Phase I)
9. Rheumatoid Arthritis Preclinical Stage Products
10. Rheumatoid Arthritis Therapeutics Assessment
11. Rheumatoid Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rheumatoid Arthritis Key Companies
14. Rheumatoid Arthritis Key Products
15. Rheumatoid Arthritis Unmet Needs
16 . Rheumatoid Arthritis Market Drivers and Barriers
17. Rheumatoid Arthritis Future Perspectives and Conclusion
18. Rheumatoid Arthritis Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States